INDEX

AAT-deficient patients, 233, 237. See also Alpha-1 antitrypsin (AAT) deficiency
ABCAI-mediated efflux, 292, 293. See also ATP-binding cassette transporter AI (ABCAI)
ATP binding cassette transporter G1 (ABCG1), 292, 293
Accreditation Council for Continuing Medical Education (ACCME), 418
Acid-citrate-dextrose (ACD) blood collection solution, 4
Acid-stabilized plasmin, as a direct-acting thrombolytic, 259–271
Acquired angioedema (AAE), 249
Acquired ATIII deficiency, 107, 108
Acquired human TSE infections, 369
Acquired immunodeficiency syndrome (AIDS), convalescent plasma treatment of, 209. See also HIV entries; Human immunodeficiency virus (HIV); National AIDS Control Organization (NACO)
Acquired inhibitors, 57
Activated clotting factors, 66
Activated Factor VII (FVIIa), 51, 69, 75
Activated Factor IX (aFIX,FIXa), 75, 81–83
Activated Factor X (FXa), 81. See also Activated purified Factor X
Activated Factor XI (FXIa), 94
Activated Factor XII (FXIIa), 242 in Factor XI activation, 94
Activated Factor XIII (aFXIII, FXIIIa), 102, 139, 140
Activated factors, in PCC products, 72
Activated Hageman factor (HFa), 193
Activated partial thromboplastin time (aPTT), 95
Activated partial thromboplastin time (aPTT) assay, 49, 50
Activated partial thromboplastin time (aPTT) test, 111, 112, 118
Activated PCC, 76. See also Activated prothrombin complex concentrates (APCCs); Prothrombin complex concentrates (PCCs)
Activated Protein C (APC), 67, 148
Activated prothrombin complex concentrate (FEIBA®), 37
composition of, 53
Activated prothrombin complex concentrates (APCCs), 49, 50
clinical trials with, 52
mechanism of action of, 51–57
Activated purified Factor X, 112. See also Activated Factor X (FXa)
Active coagulation enzymes, 51
Active lipids, 74
Active coronary syndrome (ACS), 274, 288, 289
Active hemorrhages, 57
Acute ischemic stroke, 268
Acute ITP, 220. See also Immune thrombocytopenic purpura (ITP)
Acute lung injury (ALI), 352
Acute respiratory distress syndrome (ARDS), 161, 341
ADAMTS-13 metalloprotease, 42
Adhesion molecules, expression of, 276
Adjunctive cancer therapy, ceruloplasmin in, 341
Adsorption processes, for virus removal, 364
Adsorption techniques, in plasma fractionation, 441
Advanced glycation end products (AGEs), 192
Advate®, 36
Adverse effects/events (AEs), 57, 58, 74 albumin-related, 176, 177
in ITP treatment, 220, 221
related to IVIG preparations, 198, 199
Adverse reactions blood-cell-induced, 351
related to IVIG preparations, 198, 199
Aerosol alpha-1-PI, 237, 238. See also Alpha-1-proteinase inhibitor (Alpha-1-PI)
Affinity chromatography, 33–35, 44, 84–86, 97, 105, 439, 440. See also Double affinity chromatography in albumin manufacture, 165
in FVIII manufacturing, 150
of FEIBA® components, 51
of haptoglobin, 328
on heparin gels, 149
in plasma fractionation, 441
plasminogen purification by, 314, 315
in vWF purification, 45

Aggregation, 163, 164
Aggregation formation, in IVIG preparations, 195. See also Aggregation
Aggregation preventing, 340
of viruses, 191
Albondin, 163, 164
Albumin, 437. See also Human albumin entries; Human serum albumin (HSA)
accompanying IVIG preparations, 197
aluminum limits for, 169, 170
anticoagulant activity of, 164
appropriate and inappropriate use of, 174, 175
binding properties of, 175
biochemistry of, 160, 161
burn patient benefits of, 174, 175
as carrier for nitric oxide, 164
centrifugation of, 167, 168
citrate concentrations in, 171
clinical issues related to, 171–176
color of, 169
demand for, 21, 464
demand in China for, 453
drug binding to, 163
effects of, 172, 173
esterase activity of, 164
fatty acids in, 162, 163
fluid balance and, 161
free thiol in, 171
future trends for, 177, 178
glycation of, 164
guidelines for therapeutic use of, 171
guidelines for use of, 159
haptoglobin precipitation and, 328
immunomodulatory properties of, 164
ionic properties of, 232
ligands binding to, 162–164
as a low-risk product, 176
manufacturing of, 164–171
manufacturing process development for, 166, 167
mechanism of action of, 161–164
molecular size distribution for, 171
pasteurization of, 165, 166
physiology and function of, 160
PKA activity in, 171
in plasma buffering, 164
preparation of, 159
prognostic value of, 174
properties of, 178
redox properties of, 164
role in critical illness, 160
roles of, 159, 171
as a safe plasma protein, 177
sepsis and, 176
transport and ligand binding of, 161–164
in treating liver disease, 175
Albumin concentration, 175
Albumin dialysis system, 175
Albumin fusion proteins, 178
Albumin microspheres, 178
Albumin preparations, purity of, 169, 170
Albumin production, 12
global, 159
Alkjaersig purification method, 313
Allergic PCC reactions, 75
Allergic reactions, 351–353
Alloantibodies, 37
inhibitory, 57
Alpha-1 antitrypsin (AAT) deficiency, 227–229. See also AAT-deficient patients
Alpha1-PI, 227, 228. See also Alpha1-proteinase inhibitor (Alpha1-PI)
Augmentation therapy with, 229
elastase inhibition by, 229
future of, 237, 238
isolating, 230–232
new indications for, Inc., 238
structure of, 228, 229
tryptsin-inhibitory activity of, 232
Alpha1-PI inactivation, 232
Alpha1-PI isoforms, 228
Alpha1-PI production methods, comparison of, 236
Alpha1-PI purification methods at industrial scale, 231–237
at laboratory scale, 229–231
Alpha1-proteinase inhibitor (Alpha1-PI), 227–240
Alphanate, 45
Alphanine, 88
replacement therapy recommendations for, 89
Alpha Therapeutics, 466
Aluminum limits, for albumin, 169, 170
Alzheimer’s disease, 195, 197, 200
American Association of Blood Banks (AABB), 8, 423, 425
American market, 464
American Red Cross (ARC), 5, 7, 8, 10
in blood collection, 8
fractionation capability of, 9
Analytical comparability, strategies for demonstrating, 408, 409
Analytical programs, successful, 410
Anamnestic responses, 58
Anaphylactic PCC reactions, 75
Anaphylactic reactions, 351, 352
Anaphylactoid reaction rate, for Octaplas (LG), 352
Anastomosis, 3, 4
Angioedema acquired, 249
hereditary, 241, 242, 248, 249
Angiogenic compounds, 152
Anhaptoglobinemia, 322
Animal bioassay, 375
Animal disease models, transferrin in, 306
Animal models of blood loss and replacement, 326
in investigating hemophilia therapies, 55
relevance of, 55–57
TSE-related, 371, 372
Animal parvoviruses, 328
Animal studies, haptoglobin in, 331
Animal thrombolysis studies, 265, 266
Anion(exchange chromatography (AEC), 44, 187, 189
Anion exchange chromatography procedure, 213
Anion exchangers, for PCC capture, 84
Anion exchange technology, 9
Annual Product Review, 399
Anthrax, as biological weapon, 210
Anthrax immune globulin (AIG), 212
Antibodies, 207
immobilized, 33
inhibitory, 37, 73, 74
inhibitory and noninhibitory, 57
monoclonal and polyclonal, 200
neutralizing, 191
reducing, 351
Antibody–antigen binding, 208
Antibody-based immunotherapy, 210
Antibody-based therapies, 207
Antibody concentrates, 7
Antibody degradation, 33
Antibody-dependent cellular cytotoxicity (ADCC), 208
Antibody therapy, 208
Antibody titers, in IVIG preparations, 195–197
Anticoagulant activity of, albumin, 164
Anticoagulant effect, reversal of, 73
Anticoagulants, 3
development of, 4
Anticoagulant solution, for source plasma collection, 426
Anticoagulant system, 69
Anticomplementary active aggregates, 198
Anticomplementary activity (ACA), 191, 193
of IVIG preparations, 192, 193
Anti-D immune globulin, 9
Anti-D Mab, 222. See also Monoclonal antibodies (Mabs)
Anti-D products, manufacturing process of, 221
Antifibrinolytic agents, 249
Antifibrinolytic drugs, 96
Antihemophilic Factor B, 65
Antihemophilic globulin, in hemophilia treatment, 33
Anti-HLA/HNA antibodies, 351, 352
Antihemophilic globulin, manufacture by seed-based expression, 289–295
Aplastic anemia, ceruloplasmin treatment, 338
Apheresis, plasma collected by, 439
Arteriovenous anastomosis, 3, 4
Arterial plaque, control of, 283
Arterial/venous thrombosis models, 265
Arterial plaque, role of inflammation in, 275
Atherosclerotic models, 294
Atherosclerotic lesions, 284
Atheroma volume, 288
Audit reports, 397, 399
Audit from external bodies, 398
Audit schedule, 397
Audit/inspections, 398
Augmentation therapy, with alpha1-PI, 229
Australia, plasma fractionation in, 16, 17
Australian Red Cross, 17
Autodegradation, 260–262
Auto-FIX concentrates, 49
Autoplex, 49, 50
Aventis Behring, 15, 466
"Axial flow" type columns, in plasma fractionation, 441, 442
B19 NAT, 349. See also Nucleic acid-based testing (NAT); Parvovirus B19 (B19V)
Bacterial endotoxin test (BET), 194
"Bad cholesterol," 274
Bags, peeling of plasma into, 439
Barga, 345
Batch adsorption, in plasma protein fractionation, 398
Batch mode manufacturing, solvent/detergent plasma and, 345
Baxter Bioscience, 8, 9, 21, 451, 461
growth of, 16
manufacturing strategy of, 15
Baxter Healthcare, 233, 236, 247
Bayer AG, 15
B-domain deleted FVIII product, 36, 37
Bebulin VH, 71
Bees, William, xi, 217
Behringwerke AG, 10
Benesis, 18
Berinert®, 247
Beriplex P/N, 71
Berkovsky, Aron, xi, 337
Bertolini, Joseph, x, xi, 3, 423
β-amyloids, antibodies to, 197
β-glucans, in IVIG preparations, 194
β-glucocerebrosidase, 11
Beta-hydroxylation modifications, 108
β-thalassemia, 307
Biesert, Lothar, xi, 345
Bilateral membranous conjunctivitis, 317
Bilirubin, albumin binding to, 163
Binding affinities, haptide, 120, 121
Bioactive lipids, 351, 352
Biochemical IVIG parameters, 194–198.
See also
Biogenic amines, regulation of, 339
Biolex, 290
Biological IVIG parameters, 194–198.
See also Intravenous immunoglobulin (IVIG)
Biological products, pathogen safety of, 72, 73
Biological products commercialization, licensure requirements for, 405, 406
Biological variance, 193
Biological weapons, hyperimmunes as defense against, 210–212
Biologic(al)(s) License Application (BLA), 143, 405, 406
solvent/detergent plasma and, 346
Biomarkers, of haptoglobin efficacy, 331
Biologic(al)(s) License Application (BLA), 143, 405, 406
solvent/detergent plasma and, 346
Biomarkers, of haptoglobin efficacy, 331
Biotest AG, 10, 461
Bio Products Laboratory Factor X Bio Products Laboratory concentrate, 96
Bio Products Laboratory concentrate, 96
Bio Products Laboratory Factor X properties of, 111
Bio Products Laboratory (BPL), 327, 328
Biopharmaceutical industry, contribution of, 468
Biopharmaceutical products, development/commercialization of, 403
Biopharmaceuticals, 283
Bio Products Laboratory (BPL), 327, 328
manufacturing process used by, 329
Bio Products Laboratory concentrate, 96
Bio Products Laboratory Factor X properties of, 111
Biotest AG, 10, 461
Bleeding
FXI deficiency and, 94, 95
PCCs to stop massive, termination of, 66
Bleeding control agents, 57
Bleeding control agents, 57
Bleeding disorders, treatment of, 73
Bleeding episodes, 58. See also Massive bleeding
in hemophiliacs, 37
regulation of, 105
spontaneous, 58
Bleeding events, PCC dosage for, 74
Blood. See also Hemo-entries; Plasma entries; Serum entries
infectious agents in, 361
for medical use, 4
storing, 4
TSE infectivity in, 371–373
Blood banking, early history of, 3–5
Blood banks
first, 5
in India, 19
Blood Betterment Association, 5
Blood-borne lipid-enveloped viruses (LEVs), 72, 73
Blood-borne viruses, 366
Blood-cell-induced adverse reactions, 351
Blood cell separators, 4
Blood clotting, FX zymogen and, 52
Blood coagulation, 66–68. See also Coagulation entries
Blood coagulation cascade, 122, 123. See also Clotting cascade; Coagulation cascade Blood collecting agencies, 425
Blood collection unit, sterile vacuum-type, 9
Blood components
TSE infectivity reduction studies for, 374
use of, 4
Blood contaminants, inactivating, 35
Blood Derivatives Production Centers Act, 12
Blood donation/transfusion centers, 11
Blood donor deferral policies, 374
Blood donor organizations, 10
Blood donor recruitment, 4, 5
Blood donors, paid, 12. See also Nonremonurated plasma
Blood donor screening, 376
“Blood establishment” (BE), 384, 397, 398
Blood field depots, 4
Blood groups, discovery of, 3, 4
Blood plasma, use of, 4. See also Plasma entries
Blood Plasma Corp. of Japan, 17
Blood processing industry, 5
Blood procurement, expanding, 5
Blood products, viral safety of, 189, 190
Blood Products Laboratory (BPL), 11
Blood-related viruses, removal of, 190
Blood safety programs, 20
Blood substitutes, 5
Blood testing, 427, 428
Blood transfusion, early history of, 3–5
Blood-typing globulins, 7
“Blue” proteins, 337
Blundell, James, 3
Bogdanov, Alexander, 4
Boothe, Joseph, xi, 283
Bottles, peeling of plasma in, 439
Botulism antitoxin product, 213
Botulism antitoxin (eBAT), 212
Botulism antitoxin product, 213
Bourgeois, Louise, 217
Bovine plasma, 6
Bovine spongiform encephalitis/encephalopathy (BSE), 370–372
albumin and, 177
atypical forms of, 376, 377
Bovine thrombin solution, 137
Bowl-type centrifuges, 440
Boyd, W. C., 7
Bradykinin, 242, 248, 249
Brain-derived infectivity, 375
Brazil
contract fractionation arrangements in, 458
plasma fractionation plant in, 13
BRIC (Brazil, Russia, India, China) countries, new plant investments among, 454
Buchacher, Andrea, xi, 185
Bulmer, Mark, xi, 159
Burn patients, benefits of albumin use in, 174, 175
Burn treatment, ceruloplasmin and, 341, 342
Bypassing agents, 57, 74
PCCs as, 75, 76
C1-inhibitor, 241–258
biochemistry of, 241
clinical issues related to, 248, 249
in fibrolytic treatment, 250
future trends of, 250, 251
large-scale production of, 244
mechanism of action of, 243
physiology of, 242, 243
potential clinical application of, 251
potential clinical indications for, 249, 250
in prophylactic regimens, 250
published purification methods for, 245, 246
roles of, 242, 243
C1-inhibitor capture, 247
C1-inhibitor manufacturing 243–247
virus reduction steps in, 244
C1-inhibitor measurement, international standards for, 247, 248
C1-inhibitor molecule, 248
C1-inhibitor mutations, 241
hereditary angioedema and, 248
C1-inhibitor products, characterization of, 247, 248
C1-inhibitor purification, 244–247
C1-inhibitor purified concentrate, 249
Cadaver blood, 8
Call centers, 417, 418
Canada, fractionation facilities of, 9
Canadian Red Cross, 9, 10
Cancer therapy, ceruloplasmin in, 341
Cangene, 10
Canine coronary occlusion model, 261
Canine hemophilia model, 55
Capillary electrophoresis, 263
Capillary leak syndrome (CLS), 287, 288.
See also Heart entries
Capillary leak syndrome (CLS), 287, 288.
Cardiovascular disease models, 287, 288.
Cardiovascular diseases, 277, 283
Cascade plasma fractionation processes, 38
Catheter-assisted thrombolysis, 264
INDEX 475

Catheter-assisted thrombolysis therapy, 261
Catheter-delivered plasmin, 265
Cation binding, 119
Cation(ic) exchange chromatography (CEC), 142, 189
Cation exchange chromatography procedure, 213, 214
Cations, albumin binding to, 163
Cattle-derived products, regulations for, 374
CD163 macrophage receptor, 326, 327, 331, 332
Pathological consequences of, 325, 326
toxicity of, 325, 326, 332, 331, 332
Cell membrane removal, 351
Cellular cholesterol, 286
Cell-based assays, 375
of haptoglobin, 330
Cell culture
fibrinogen-based products for, 125, 126
recombinant FVIII production in, 36, 37
Cell-free hemoglobin (CFH), 321, 324–327, 330, 331
pathological consequences of, 325, 326
toxicity of, 325, 326, 331, 332
Cell membrane removal, 351
Cellular blood components, vCJD
Cellular cholesterol, 286
Centro company, 15
Center for Biologics Evaluation and Research (CBER), 404
Central Drugs Standard Control Organization (CDSCO), 20
Central Laboratory of the Netherlands Red Cross (CLB), 14
Central regulatory systems, role of, 67, 68
Centre National de Transfusion Sanguine (CNTS), 11
Centre Régional de Transfusion Sanguine (CRS), 247
Centres of Excellence, 15
Centrifugation
in albumin manufacture, 167, 168
continuous-flow, 4
in ethanol fractionation, 440
intermittent flow, 4
Ceruloplasmin (CP), 337–344. See also CP entries
as an acute inflammatory phase protein, 339
as an adjunctive cancer therapy, 341
administration of, 340
anti-inflammatory action of, 339
antioxidant activity of, 338, 342
in aplastic anemia treatment, 340–342
biogenic amine regulation by, 339
biological functions of, 337–339
clinical effectiveness of, 342
clinical uses of, 340–342
as copper carrier and copper cycle regulator, 338
in emergency medicine, 341, 342
ferrioxidase action of, 338
manufacture of, 339, 340
pharmaceutical indications for, 340
structure and function of, 337, 338
Cetoril, 244
CFH removal. See also Cell-free hemoglobin (CFH)
cGMP compliant equipment, in plasma fractionation, 441. See also Current good manufacturing practice (cGMP) guidelines
Chain-cleavage reactions, 123
Change, actions to execute, 397
Change control philosophy, 392
Change control process, 396, 397
Chemical virus inactivation, 364, 365
Chemo-Sera Therapeutic Research Institute, 18
China
demand for albumin in, 453
plasma fractionation in, 18, 19
China National Blood Products Corporation, 18
Cholate-based method, 292
Cholesterol efflux, 292, 293
Cholesterol ester (CE), 284
Cholesterol ester transfer protein (CETP), 284, 286
Cholesterol homeostasis, 283, 284
Cholesterol levels, safflower-derived apolipoprotein AlMilano:POPC and, 292, 293
Cholesterol metabolism, 275
Cholesterol transport, 274, 275, 283
Cholesteryl ester transfer protein (CETP), 273, 274
Christmas factor, 65
Chromatographic purification methods/techniques, 105, 124
Chromatographic resins, in plasma fractionation, 441
Chromatographic separation process, 221
Chromatographic technology, 11, 13
Chromatography
in human serum albumin manufacture, 166
in plasma fractionation, 441
Chromatography-based purification method, for alpha1-PI, 230
Chromatography methods, for isolating proteins, 38
Chromatography polishing, 188
Chronic intoxication, ceruloplasmin and, 341
Chronic ITP, 219, 220. See also Immune thrombocytopenic purpura (ITP)
Chitourou, Sami, xi, 31, 41, 93
CIP fluids, 168. See also Clean in place (CIP) centrifuge design
Circulatory volume, albumin and, 175
Cirrhotic ascites, 175
Citrate concentrations, in albumin, 171
Cleaning procedures, validation of, 394
Clean in place (CIP) centrifuge design, 167. See also CIP fluids
Cleavage loop (CL), in plasminogen, 311
Clinical coagulation tests, 118
Clinical efficacy, of products, 406
Clinical-grade plasmin, manufacturing of, 261–264
Clinical safety, of plasma-derived products, 406
Clot formation, 139, 140. See also Coagulation entries; Thromb-entries
Clot parameters, 119
Clotting cascade, FVIII during, 32. See also Blood coagulation cascade; Coagulation cascade
Clotting Factor VIII, 31–40. See also Factor VIII (FVIII)
gene structure and function/regulation of, 31, 32
immune tolerance to, 37, 38
nanofiltering, 36
production methods for, 33–35
Clotting factors, activated, 66
Clotting pathways, 82
Clotting-related proteins, 7
Clotting time (CT), simulating, 118, 119
Coagulant factor therapy, 35. See also Clot-entries
Coagulation cascade, 94, 122, 123. See also Clotting cascade activators in, 59
Coagulation disorders, replacement therapy for, 46
Coagulation FVIII interaction, vWF protein and, 42, 43
Coagulation Factor IX, 88. See also Factor IX (IX)
Coagulation factor concentrates, 106
Coagulation factors, 59, 81
deficiencies of, 67, 68
elevated levels of, 68
mutations in, 75
of prothrombin complex, 65
Coagulation factor treatment, access to, 37
Coagulation mechanisms, alternative, 123
Coagulation pathway physiology, 66–68
Coagulation products, safety of, 38
Coagulation factor concentrates, 106
Coagulation factor treatment, access to, 37
Coagulation mechanisms, alternative, 123
Coagulation pathway physiology, 66–68
Coagulation products, safety of, 38
Coagulation factor concentrates, 106
Coagulation factor treatment, access to, 37
Coagulation mechanisms, alternative, 123
Coagulation pathway physiology, 66–68
Coagulation products, safety of, 38
Coagulation factor concentrates, 106
Cohn, Edwin J., 4, 5–7, 423, 437
Cofact, 71
Code of Federal Regulations (CFR), 385, 423
Cofact, 71
Cohn, Edwin J., 4, 5–7, 423, 437
plasma fractionation industry and, 7, 8
Cohn I precipitate, 141. See also Cohn Fraction I precipitate
Cohn IV-1 precipitation conditions, 232. See also Cohn Fraction IV entries
steps in, 150
Cohn-Chromatography process, 17
Cohn Fraction I precipitate, 102. See also Cohn Fraction I precipitate
Cohn Fraction IV, transferrin from, 303
Cohn Fraction IV-1, in ceruloplasmin manufacture, 339
Cohn Fraction IV-1, 4 pastes, 230, 231–233, 235–237
Cohn fractionation method/process, 33, 43, 164, 186, 187, 437. See also Cohn’s Method
transferrin from, 303
Kistler–Nitschmann fractionation method vs., 165
Cohn/Oncley fractionation process, 191, 213, 262, 407
Cohn’s Method, 11, 221. See also Cohn fractionation method/process modifications to, 12
purification of hyperimmune immunoglobulin and, 212
Cold ethanol fractionation, 363
Cold ethanol fractionation processes, 262
Cross-functional communication channels, 421
Cryopoor plasma, 431, 432, 439
Cryoprecipitate(s), 44, 102, 141, 375 fibrogen from, 123, 124 in hemophilia treatment, 33
Cryoprecipitation, in plasma protein collection, 438, 439
Cryo-rich plasma, 432, 439
Cryosupernatant, 456
Crystalloids, 172
CSL-112 formulation, 278, See also Commonwealth Serum Laboratories (CSL)
CSL Behring, 15, 234, 236, 237, 451, 461, 466
CSL Ltd., 17, 21 growth of, 16
CSL process, 234 “Cup and saucer” architecture, 94
Curling, John, x, xi, 3, 451
Current good manufacturing practice (cGMP) guidelines, 429, 444, 445. See also cGMP compliant equipment
Cutter Laboratories, 8
Cutter purification process, 232, 233
Cyclic adenosine monophosphate (cAMP), 293
Cyclic Fenton reaction, 123
Cysteine residues, in haptoglobin, 323
Cysteine
in albumin, 161 in FXI molecular structure, 93
Cysteine residues, in vWF protein structure, 42
Cystic fibrosis, 238
Dalton, Joan, xi, 321
“Dead-end” filtration, in plasma fractionation, 443
DEAE-Cellulose, 84, 244
DEAE-Sephadex®, 83, 84, 108, 213, 244, 247, 313, 439, 445
DEAE-Sepharose® FF, 70, 83, 84 in albumin manufacture, 165
Dempster, F. J., 16
Denatured FVIII, 37. See also Factor VIII (FVIII)
Denmark State Serum Institute, 14
De novo donors, 221
Depth filters, 440
Des-1,2-ApoAI Milano, 291, 292. See also Apolipoprotein AI Milano (ApoAI Milano)
Desiccated plasma, 5
Design of experiments (DoE), 389, 390, 407
Design qualification (DQ), 391
Design space, 389, 390
Desmopressin (DDAVP), 43, 96
Deutsches Rotes Kreuz (DRK) Blutspendedienst Nordrhein-Westfalen, 345. See also German Red Cross (DRK)
Developing countries/nations
blood collection improvements within, 454 dependency on plasma products, 458 providing plasma products to, 453, 454
Developing countries needs, addressing, 465, 466
Developing markets, growth potential of, 468
Deviations dealing with, 393–396 process flow for handling, 395
Dextran sulfate affinity resins, 85
Diabetes, therapeutics for, 283.
Diabetes, Type 1 diabetes
Diafiltration in alpha1-PI purification, 230, 231 in plasma fractionation, 442
Diatomaceous earths, filter aids based on, 168
Dichtelmüller, Herbert, xi, 361
Diphtheria, antibodies to, 195, 196
Direct-acting thrombolitics, acid-stabilized plasmin as, 259–271
Direct transfusion, 3, 4
Diseases. See also Alzheimer’s disease; Atherosclerosis; Cardiovascular diseases; Diabetes; Emphysema; Graft-versus-host disease (GVHD); Hemolytic disease of the fetus and newborn (HDFN); Hemolytic disease of the new born (HDN); Hepatitis entries; Infectious diseases; Ischemic heart disease; Lignase domain; Ligneous disease; Matern-tumor (LTP); Liver disease; Pancreatitis; Polio; Prion diseases; Pseudomembranous disease; TSE diseases; Variant Creutzfeldt-Jakob disease (vCJD); Viral diseases; Wilson–Konovalov disease as biological weapons, 210–212 pulmonary, 228 rare, 101, 462, 463 reconstituted HDL replacement therapy for, 277 transmission of, 151
Disease state plasma, 212
Disposables, 445
Disruptive processes, 445
Disseminated intravascular coagulation (DIC), 152
Disulfide bonds, in haptoglobin, 323
Disulfide bridges, in alpha1-PI, 230, 231
Divalent cations, albumin binding to, 163
Donor selection, 361, 366 “Donor stim” program, 213
Dosage optimization, for PCCs, 74
Dose-efficacy relationship, 89
Double affinity chromatography, 85, 86
Drew, Charles, 5, 10
Dried human plasma, 6
Drugs albumin binding to, 163 binding and transport of, 163 binding to fibrinogen, 119, 120 HDL-increasing, 273
Dry fibrin glue formulations, 143
Dry heat treatment, 35, 87
DTT treatment, 234
Duran-Jordà, F., 10
Dysplasminogenemia, 315
Early generation PCCs, thrombotic events with, 66
ECH-Lysine Sepharose resin, 314
Economic growth, 18
Economics, of plasma fractionation, 451–460
Edsall, John T., 7
Educational grants, 418
Efficacy, preclinical evidence of, 264–267
Efficacy studies, 264–266
Economic Organization for Biological and Vaccine Production (Vacsera), 20
Ehrlich, Hartmut, xi, 413
Ehrlich, Paul, 5
VIIISelect affinity matrix, 38
Elastase, alpha1-PI inhibition of, 229
INDEX 477
INDEX

Elastase, 227, 228
Electrophoresis, of haptoglobin, 330
Electropinning fibrinogen fibers, 125
Elastic interactions, haptoglobin
quaternary structure and, 323
Elsinger, Fritz, 50, 51
Electrospun fibrinogen fibers, 125
Electrophoresis, of haptoglobin, 330
Elastase, 227, 228
European Directorate for the Quality of
Medicines and HealthCare (EDQM), 429
European fractionation industry, 10–13
European governments, Red Cross
and, 11–13
European guidelines, for plasma
collection, 424
European market, 463, 464
European Medicines Agency
(EMA), 318, 362, 384, 467
European Medicines Agency Committee
for Medicinal Products for Human
Use (EMEA/CHMP), 66
European Pharmacopoeia (EP), IVIG
parameters defined by, 191–194
European Pharmacopoeia Monograph
1223, 87, 88
European Union (EU). See also EU GMP
regulations
plasma standards in, 425
rare disorders in, 101
Exogenous infectivity, reduction studies
with, 375, 376
Exosites, 139
Expanded bed chromatography, 446
External audits, 399
Extracellular matrix (ECM), 119
Extrinsic clotting pathway, 82
Eye drop plasminogen concentrate, 311
Erythroblastosis fetalis, 217
Esterase activity, of albumin, 164
Etablissement Francais du Sang
Aquitaine-Limousin, 345
ETC216 (1-palmitoyl-2-oleoyl
phosphatidylcholine), 288, 289, 292
Ethernet-based precipitation methods, 7
Ethanol fractionation, 186, 187, 440.
See also Cold ethanol fractionation
entries
in human serum albumin
manufacture, 166
Ethicon, 20
EU GMP regulations, 386. See also
European Union (EU)
Europe
AAT deficiency in, 228
fibrin glues in, 137
for-profit fractionation in, 12, 13
legal plasma-regulatory documents
in, 385
multinational fractionation industry
in, 14–16
not-for-profit fractionation in, 11–13
not-for-profit sector consolidation
in, 14
plasma collection in, 21
plasma fractionation in, 13
plasma manufacture in, 384, 385
FVIII protein, structure and function
of, 31, 32
FVIII protein synthesis, 31
FVIII replacement, 33
FVIII variants, 38
FVIII/vWF–heparin interaction, 45
FVIII/vWF-rich plasma fraction, 43
FIX activation, 85. See also Factor IX
FIX, antihemophilic Factor B, (Christmas factor)
FIX concentrates, 52, 73
clinical efficacy of, 89
FIX deficiency, 49, 73
FIX dosing, 88
FIX manufacture, processes used in, 87
FIX product yield, 87
FIX units, 74
FX activation, 32. See also Factor X (FX,
Stuart–Prower factor)
FX separation, 85
FXa inhibition, 243. See also Factor XI
(FXI)
FXa procoagulant activity, 199
FXI binding, 59
FXI cleavage, 94
FXI coagulation activity, 95, 96
FXI concentrates, 97
FXI zymogen crystal structure, 94
FXIII-A subunit, 102. See also Factor
XIII (FXIII, fibrin stabilizing factor)
deficiency of, 105
FXIII-B subunit, 102
FXIII concentration, 142
FXIII-A subunit, 102

See also
Factor I
Factor II (FII, prothrombin); Factor
Xa (FXa); Prothrombin entries
Factor VIII (FVIII), 439. See also
Fibrinogen (Factor I)
Factor II (FII, prothrombin), 65, 69. See also Factor
V (FV)
Factor VII concentration, 66
Factor VIII (FVIII); Plasma-derived FVIII
Factor VIII coagulant activity, 51
Factor VIII concentrates, 37
Factor VIII-deficient hemophilic dog, 55
Factor VIII gene, 31
Factor VIII immunogenicity, 37
Factor VIII-inactivating inhibitors, rescue
therapy for patients with, 37, 38
Factor VIII infusions, 37
Factor VIII inhibitor plasma, 53, 54
Factor VIII inhibitors, therapeutic approaches
for, 57
Factor VIII molecule, improving expression
levels of, 36, 37
Factor VIII mutations, 31
Factor VIII products, improvement of, 44
FVIII alternatives, 439. See also
Clotting Factor VIII; FVIII entries;

Human plasma coagulant
Factor VIII; Plasma-derived FVIII;
Plasma-derived FVIII; Purified

Factor VIII; Recombinant Factor VIII
(rFVIII)
inhibitors and, 57
Index

prophylactic therapy with, 58
risk of contamination of, 375
sales of, 452
Factor VIII inhibitor bypassing activity (FEIBA®), 49–63, 65
active principle of, 51–57
clinical use/experience with, 57, 58
in FVIII-deficient plasma with inhibitors, 59
inhibitor bypassing potency of, 52, 53
as multicomponent therapeutic agent, 59, 60
pharmacokinetic properties of, 57
Factor VIII products, 34, 467
Factor IX (FIX, antihemophilic Factor B, Christmas factor), 65, 69, 81–92.
See also FIX entries
biochemical characteristics of, 68
biochemistry and physiology of, 81–83
clinical aspects of, 88, 89
posttranslational modifications of, 83
prophylactic therapy with, 58
sales of, 452
Factor IXa-α, 82
Factor IX catalytic domain, 82
Factor IX concentrates
developing high-purity, 87
flow diagram for, 85
highly purified plasma-derived, 86
production processes for, 83–87
Factor IX concentration, 66
Factor IX gene, 81
Factor IX isolation, techniques used for, 84
Factor IX products, 82, 83, 467
process comparison for, 86
purification methods of, 85
Factor IX purification, 84
Factor X (FX, Stuart–Prower factor), 65, 101, 107–111. See also FX entries
biochemical characteristics of, 68
biochemistry of, 108
clinical issues related to, 110, 111
future trends for, 111, 112
indications for, 112
in prothrombin complex concentrates, 108
manufacturing of, 108–110
physiology of, 107, 108
Factor Xa (FXa), 51, 53, 69. See also FII-FXa complexes
prothrombin protection by, 59
role of, 53–55
Factor X activation, 107
Factor Xa inactivation, 107
Factor X concentrate
functionality of, 111
safety profile of, 111
therapeutic, 108
toxicity of, 111
Factor X concentration, 66, 110
Factor X deficiency, 107
bleeding patterns of, 107
substitution therapy for, 110
Factor X gene, 107
Factor X manufacturing process, characteristics of, 111
Factor X potency, 110
Factor X products, development of, 108
Factor X safety concerns, 110, 111
Factor X-specific activity, 108, 110
Factor X zymogen, 52
Factor XI (FXI), 93–99.
See also FXI entries
Factor XI (FXI) mutations, 95
Factor XI inhibition, by plasma inhibitors, 95
Factor XI dimerization, 93
Factor XI gene structure, 95
Factor XI activation, 94
Factor XI concentrates, 96
Factor XI deficiency management of, 95, 96
understanding, 97
Factor XI dimerization, 93
Factor XI gene structure, 95
Factor XI inhibition, by plasma inhibitors, 95
Factor XI mutations, 95
Factor XII (FXII), in Factor XI
activation, 94
Factor XII (FXII), in Factor XI
activation, 94
Factor XIII (FXIII, fibrin stabilizing factor), 101–107, 139. See also FXIII entries
binding sites for, 138, 139
biochemistry of, 102
clinical issues related to, 105, 106
freeze-dried, 104
future trends for, 111, 112
manufacturing of, 102–105
physiological roles of, 102
physiology of, 101, 102
Factor XIII activity, 107
functional assays for, 107
Factor XIII concentrate pasteurization, virus inactivation by, 106
Factor XIII concentrates
characterization of, 106, 107
indications for, 112
manufacture of therapeutic, 103
Factor XIII deficiency, 102
Factor XIII process, characteristics of, 105
Factor XIII product, properties of, 105
Factor XIII purification procedures, modification of, 104, 105
Factor XIII purity, 107
Factor XIII replacement therapy, efficacy of, 106
Factor XIII subunits, 101, 102
Falksveden fractionation scheme, 187, 188
False Claims Act, 414
Fantus, Bernard, 5
Farhood, Ramin, xi, 413
Fatty acid binding, to fibrinogen, 124
Fatty acids, in albumin, 162, 163
Favism, haptoglobin in treating, 330
Fc function, in IVIG preparations, 195
Fc section, 207, 213
FDA Blood Products Advisory Committee, 424. See also Food and Drug Administration (FDA)
FDA meeting, recommendations for, 404, 405
Feasibility Study, for SAPG, 21
Feed bans, 374
FEIBA® components, affinity chromatography of, 51. See also Factor VIII inhibitor bypassing activity (FEIBA®)
FEIBA® NF, manufacture of, 50
FEIBA® NF prophylactic treatment, 58
FEIBA®/NovoSeven® Comparison (FENOC) study, 58
FEIBA® products, efficacy and safety of, 57, 58
FEIBA® unit, 49, 50
FEIBA® VH, 58
Feldman, Peter, xi, 101
Fenton reactions, 123
Fibrin, 312, 313
classic blood coagulation cascade leading to, 122, 123
interaction with plasminogen, 140
interaction with tissues, 140
Fibrin associations, haptide contribution to, 121, 122
Fibrin bandages, 143
Fibrin clot, 81
as hydrogel, 137
Fibrin clot dissolution, plasmin in, 259, 260
Fibrin clot formation, 66, 81, 139, 140
Fibrin degradation, 139
Fibrin degradation products, 140
Fibrin glue producers, 137, 138
Fibrin glues, 137–145
biochemistry of, 137, 138
clinical use of, 144
downstream steps in manufacturing, 141
fibrinogen component of, 137, 141, 142
future perspective on, 144
Fibrinogen (Factor I), 102, 117–135, 138, 139. See also FI-C precipitate binding of molecules to, 119, 120 cell attachment activity of, 120 exposure to free radicals, 123 fatty acid binding to, 124 haptide epitopes in, 120 heat stability of, 117–119 hydrophobicity of, 120, 124 hygroscopic nature of, 118 intracellular biosynthesis of, 117 metabolites and drugs that bind to, 119 minimal concentration of, 118 new forms and composites of, 125 production of, 123, 124 spray-dried, 143 structure and composition of, 117 variants of, 117 Fibrinogen associations, haptide contribution to, 121, 122 Fibrinogen-based products for cell culture, 125, 126 future prospects for, 126 Fibrinogen binding, 119 Fibrinogen component, 137 production of, 141, 142 Fibrinogen concentrates, 142 Fibrinogen concentration, clotting time and, 118, 119 Fibrinogen domains, 117, 118, 138, 139 Fibrinogen epitopes, 120–122 Fibrinogen molecule, 117, 138, 139 Fibrinogen packaging/applicators, 126 Fibrinogen polymerization induced by thrombin activation, 118, 119 turbidity and phase change during, 118 Fibrinogen preparations, 124 viral inactivation in, 124 Fibrinogen removal, 104 Fibrinogen stabilization, 141 Fibrinogen standard, 124 Fibrinolysis, 140 Factor XI and, 95 role of plasminogen in, 312 Fibrinolysis inhibitors, 141, 142 Fibrinolytic system C1-inhibitor role in, 243 main purpose of, 260 regulation of, 242 Fibrinopeptide A (FPA), 139 Fibrinopeptide B (FPB), 139 Fibrin polymerization reactions, 122 Fibrin protofibrils, 119 Fibrin stabilizing factor, 139. See also Factor XIII (FXIII, fibrin stabilizing factor) Fibrin tubes/stents, 125 Fibrogammin®, 105 Fibrolytic treatment, C1-inhibitor in, 250 Filling process, in plasma fractionation, 443 Filter aids, based on diatomaceous earths, 168 Filter presses, 440 Filtration, 354 in ethanol fractionation, 440 in the plasma fractionation industry, 168 for virus removal, 363, 364 Filtration technology, 440 Finnish Red Cross Blood Transfusion Service, 11 Finnish Red Cross fractionation plant, 14 Finnzyme®, 251 Five Layer Safety Net, 426, 429 Flebogamma 5% DIF preparation, 187, 189 “Flèbula,” 10 Flexbumin, 169 Flood Review, 17 Fluorescence intensity, 53 Food and Drug Administration (FDA), 404, 414, 423, 467 guidance on comparability from, 408 qualification/validation guidelines by, 391, 392 TSE clearance studies and, 375, 376 Food-borne vCJD cases, 370, 371 Formalin-stabilized human serum, 11 Formulation process, in plasma fractionation, 443 For-profit fractionation, in Europe, 12, 13 Foster, P. R., 11 Fractionated placental serum, 11 Fractionation. See also Caprylate fractionation; Cascade plasma fractionation processes; Chromatographic fractionation; Cohn fractionation process; Cohn/Oncley fractionation process; Cold ethanol fractionation processes; Commercial plasma fractionation facilities; Contract fractionation; Ethanol fractionation; European fractionation industry; Faksalven fractionation scheme; Finnish Red Cross fractionation plant; For-profit fractionation; Ion exchange chromatographic fractionation technology; Kistler–Nitschmann fractionation method; Multinational fractionation industry; Not-for-profit fractionation; Octanoic acid fractionation; Plasma fractionation entries; Plasma protein fractionation entries; Regional fractionation centers; Small-scale fractionation; Subfractionation methods; Toll fractionation in North Africa, 20, 21 in the Middle East, 20, 21 not-for-profit, 11–13 plasma for, 423–436 Fractionation centers difficulties in maintaining, 14 in Japan, 17 Fractionation economics, 452 Fractionation facilities, in China, 18 Fractionation industry, 101 companies dominating, 21 Fractionation intermediates, exchanging, 408 Fractionation processes, 50 Fractionation products, clinical use of, 7 Fractionators in China, 19 commercial, 7, 8 Fraction facilities, decrease in, 14 Fraction I paste, 123 Free cholesterol (FC), 284 Free radicals, 164 fibrinogen exposure to, 123 Free thiol, in albumin, 171 Freeze-dried Factor XIII, 104 Freeze-dried PCCs, 70 Freeze-dried plasma, 5, 9, 11 Freeze-drying technology, 10 Frenzel, Wolfgang, xi, 345 Fresh frozen plasma (FFP), 4, 96, 110, 350–353, 430 European guidelines for collecting, 424 Frozen plasma, 438, 439 Fusion protein, 290, 291 Fusion protein therapeutics, albumin in, 178 Gamma-carboxylated factors, 68 Gammagard liquid process steps, 189 Gamunex process steps, 187 Gelatin plasma expander, 10 Gel filtration in plasma fractionation, 441 in vWF purification, 44, 45
INDEX 481

Gel filtration chromatography, 33
Gelmont, David, xi, 413
Genereux, Maurice, xi, 207, 217
Gene therapy, 97
Genetic ATIII deficiency, 147. See also Antithrombin III (ATIII)
German Red Cross (DRK), 14. See also Deutsches Rotes Kreuz (DRK)
Blutspendedienst Nordrhein-Westfalen
German Red Cross centers, 12
Glaser purification method, 230, 231
GlassiaTM purification process, 235–237
Global fractionation capacity, 21
Global hemostatic function, assessment of, 111
Global Medical Affairs departments emerging roles of, 413–422
inside communication and, 420, 421
outsourcing by, 417, 418
publication strategy and, 417
Global Medical Affairs function, 415
Global plasma industry, 466
Global regulatory environment, 403
β-Glucans, in IVIG preparations, 194
β-Glucocerebrosidase, 11
Glucose 6 phosphate dehydrogenase (G6PD), haptoglobin in treating, 330
Glutamic acid (GLA) domain, 81
Glutamic acid (Gla) residues, 108
Glycation, of albumin, 164
O-Glycosylation, 151
N-Glycosylation sites, 93
Glycosylation variants, 303
GMP compliance, 437. See also Good manufacturing practices (GMP)
state of, 397
GMP guidelines, 429
GMP information, 387
Golgi apparatus, proteolytic processing in, 41
“Good cholesterol,” 274
Good development practice (GDP), 386
Good laboratory practice (GLP), 386–389
Good manufacturing practices (GMP), 386–389, 399, 423
in plasma collection/ manufacture, 383
solvent/detergent plasma and, 345
Goss, Neil, xi, 3, 451
Government–company relationships, 466, 467
Graft-versus-host disease (GVHD), 307
Grancha, Salvador, xi, 81
Green Cross Corporation, 17, 18, 327
manufacturing process used by, 329
Gregori, Luisa, xi, 369
Grifols Bioscience, 451, 461, 466.
See also Laboratorios Grifols
Grifols Lucas, J. A., 10
Grifols plasmin production process, 262, 263
Grifols Roig, J. A., 10
Grifols SA, 233
Guidance documents, 404
“Guidance on Qualification of Existing Equipment,” 393
Guideline of Plasma-derived Medicinal Products, 444, 445
Gulle, Heinz, xi, 137
HSN1 influenza, convalescent plasma treatment of, 210
Haemate P, 44
Haen, P. J., 12
Haptidine aggregation, 120, 121
Haptidine epitopes in fibrinogen and other proteins, 120
in protein chains, 122
Haptidine–haptidine (Hap–Hap) interactions, 121, 122
Haptides contribution to fibrin(ogen) associations, 121, 122
hydrophobicity of, 120
Haptoglobin (Hp), 169, 321–336. See also Hp entries
active sites of, 323, 324
as an acute phase protein, 325
administration of, 331
in animal studies, 331
biological properties of, 327
characterization of, 328–330
clinical issues related to, 330, 331
future trends in, 331, 332
genetics and biochemistry of, 321–324
hemoglobin binding by, 326
manufacture of, 327, 328
multiple infusions of, 331
physiology of, 324–327
potency of, 330
primary function of, 325
primary structure of, 322, 323
prophylactic, 330
quantitation of, 329, 330
quaternary structure of, 323
secondary structure of, 323
as a sequestrator of free hemoglobin, 325, 326
tertiary structure of, 323
toxicity of, 331
usage of, 330–332
Haptoglobin efficacy, 331
biomarkers of, 331
Haptoglobin–hemoglobin (Hp–Hb) complex, 321, 324, 326, 327
Haptoglobin multimers, identification and characterization of, 329
Haptoglobin precursor, 322
HAS products, 169. See also Human albumin solutions (HAS)
HAV antibody levels, 197. See also Hepatitis A virus (HAV)
Hayes, Timothy, xi, 423
HDL–cholesterol, secretion of, 287, 288.
See also High-density lipoprotein (HDL)
HDL-increasing therapies, 273, 279
HDL manufacturing process, 276
HDL metabolism, 284–286
HDL particle size, 291, 292
HDL therapy, 286–289
in cardiovascular disease risk reduction, 287
efficacy of, 287, 288
HDN Mab candidates, 222. See also Hemolytic disease of the newborn (HDN); Monoclonal antibodies (Mabs)
Health Canada, 9
Healthcare, evolving landscape of, 415
Healthcare environment, transparency in, 413
Health economics outcomes research (HEOR), 419, 421
Heart damage, iron depositions and, 301.
See also Cardiovascular disease entries; Myocardial infarction
Heat treatment of IVIG solutions, 190
Hedrich, Hans Christian, xi, 137
Heger, Andrea, xi, 345
Hemagglutinins, IVIG preparations
Hematuria, 14
Hemin, 326
Hemodialysis catheter occlusions
Hematology
Hemasure, 14
Hemoglobin, 325, 326
Hemolytic disease of the newborn (HDN), 351. See also HDN Mab candidates
Hemophilia, 31
  temporary, 55
  transformation of, 38
Hemophilia A, 31
  inhibitor development in, 57
  replacement therapy for, 57
Hemophilia A treatment, 33
  complications of, 37, 38
Hemophilia B, 49, 73, 88
Hemophilia B treatment, 89, 90
Hemophilia C, 93
Hemophiliaics, bleeding episodes in, 37
Hemophilia therapies, animal models in investigating, 55
Hemophilia treatment milestones in, 32
  morbidity and mortality in, 37
Hemorrhages, intracranial, 219
Hemorrhagic events, therapeutic approaches for, 57
Hemostasis
  pathophysiology of, 59
  regulation of, 66–68
  thrombin solutions for, 142, 143
  vWF protein role in, 42
Hemostasis evaluations, 351
Hemostasis regulators, 65
Hemostatic balance, 68, 75
Hemostatic products, need for, 143
Hemostatic regulatory proteins, 69
  in PCC products, 70
Hemostatic safety studies, 266
Hemostatic system, 74
Hemovigilance, 384, 385
Heparin, 52, 69, 70
  in PCCs, 75
  thrombin inhibition and, 139
Heparin-based resins, 85
Heparin binding site, of antithrombin III, 148
Heparin gels, 149
Heparin induced thrombocytopenia (HIT), 75
Heparin Sepharose FF, 85
Heparin–Sepharose k (HS), 96
Heparin sulfate proteoglycans (HSPGs), 148
Heparin therapy, 152
Hepatitis A virus (HAV), 72, 73, 349.
  See also Liver disease
Hepatitis B, 72, 73, 349
  antibodies to, 196, 197
  in virus validation studies, 362
Hepatitis B immune globulin/immunoglobulin (HBIG), 20, 209
Hepatitis B infection, 12
Hepatitis B surface antigen (anti-HBs), 209
Hepatitis B vaccine, plasma-derived, 9
Hepatitis B virus (HBV)
  antibodies to, 196
  transmission risk for, 348
Hepatitis C infections, 12
Hepatitis C virus (HCV), 35
  transmission risk for, 348
Hepatology, albumin in, 175
Hereditary angioedema (HAE), 241, 242, 248, 249
  diagnosis of, 249
  products for treating, 250, 251
Herring, Steven, xi, 81
Hetzl, Ernst, xi, 81
Hexyl-Sepharose, 244
High barrier-to-entry/investment cost, 461, 462
High-density lipoprotein (HDL). See also HDL entries; Reconstituted HDL (rHDL)
  antiatherogenic activities of, 275
  antiatherogenic function of, 286
  apolipoprotein components in, 275
  biogenesis of, 274
  heterogeneity of, 286
  physiological function of, 284
  physiology, biochemistry, and mechanism of action of, 274–276
  pleiotropic effects of, 275, 276
  reconstituted, plasma-derived, 273–282
High development countries, 465
Highly purified Factor X, 108–110.
  See also High-purity entries
Highly purified plasma-derived FIX concentrates, 86
High molecular weight kininogen (HMWK), 242
High molecular weight kininogen binding, 93, 94
High performance liquid chromatography (HPLC), 263
High purity alpha1-PI, 235
High-purity Factor IX, 235
High-purity Factor IX, self-sufficiency and, 89, 90
High-purity Factor IX pharmacological monographs, 87, 88
High-purity IgG preparations, 188. See also Immunoglobulin G (IgG)
High-purity products, 33, 408, 409
High-purity vWF concentrate, 44–46
High quality plasma, availability of, 454
High specificity, of antibody-based therapies, 207, 208
HIV infections. 12. See also Acquired immunodeficiency syndrome (AIDS); Human immunodeficiency virus (HIV)
  ITP secondary to, 219
HIV infections, 12
  therapy, 152
Hoechst AG, 15
Holotransferrin, 304, 306
Homosolvent Factor IX, 71
Hoppe, Hans, 221
Hp genes, 321, 322. See also Haptoglobin (Hp)
Hp phenotypes, 321, 322
  differences among, 327
  monomer units for, 324
Hp precipitation, 328
Hp synthesis, 321, 324
  impact of hemolysis on, 324, 325
Hp turnover, 324, 325
  in animals, 325
HSA infusion, 175. See also Human serum albumin (HSA)
HSA products, 169
HT DEFIX, 71
Human albumin, 6, 7
Human albumin solutions (HAS)
  specifications for, 169–171
  tests and limits for, 169, 170
  in therapeutic plasma exchange, 175, 176
Human blood transfusion, early history of, 3
Human development index (HDI), 465
Human Factor X (FX) zymogen, 52
Human immune serum globulin, 7
Human immunodeficiency virus (HIV), 35, 72. See also HIV infections
  transmission risk for, 348
  in virus validation studies, 362
Human plasma
  dried, 6
  fractionation of, 6
  intravenous immunoglobulin G from, 185–205
Human plasma-based hyperimmune products, 210–212
Human plasma coagulant Factor VIII, production and clinical profile of, 31–40
Human plasma-derived products, outlook for, 468
Human plasma-derived von Willebrand Factor, production and clinical profile of, 41–48
Human plasma fibrinogen, 138
Human plasma proteins, recombinant plasma proteins vs., 467, 468
Human plasma substitute, 6
Human plasminogen gene, 311
Human sCJD, 373. See also Sporadic CJD (sCJD); Variant Creutzfeldt–Jakob disease entries
INDEX 483

Human serum, formalin-stabilized, 11
Human serum albumin (HSA), 159–183
characteristics and specifications of, 168–171
clinical issues related to, 171–176
future trends for, 177, 178
guidance for use of, 174
ligands binding to, 162
managing critically ill with, 172
manufacturing processes for, 166
molecular structure of, 160, 161
as a NO carrier, 177
physiology and function of, 160
safety of, 176–178
in therapeutic plasma exchange, 175, 176
Human serum albumin (HSA)–fatty acid complexes, 162, 163
Human transferrin, characterization of, 305
Human vCJD, 372, 373. See also Sporadic CJD (sCJD); Variant Creutzfeldt-Jakob disease entries
Hustin, Albert, 4
HVC units, 444
Hydrophobic interaction chromatography (HIC), 234, 263, 328
in plasma fractionation, 441
Hydrophobicity, of fibrinogen, 120, 124
Hydrops fetalis, 217
Hydroxyethyl starch (HES), 172
Hydroxylation modifications, 108
Hyland Laboratories, 9, 49, 50
Hyperfibrinolysis, 351
Hyperimmune globulins, 209
Hyperimmune immunoglobulin G, 207–216
complement activation and, 208
Hyperimmune immunoglobulin products, 211
development of, 209
worldwide market in, 215
Hyperimmune immunoglobulins, 210–212
production of, 212, 213
Hyperimmune initiatives, past, 214
Hyperimmune passive
immunotherapy, 209, 210
Hyperimmune plasma, 433
Hyperimmune products, 10, 22
human plasma-based, 210–212
production of, 9
Hyperimmunes, 214
as defense against biological weapons, 210–212
Hyperimmune therapy, 210
Hyperoncotic albumin, 172
Hypoplasminogenemia, 315
Hypotransferrinemia, 306
Iatrogenic CJD, 369. See also Variant Creutzfeldt-Jakob disease entries
ICH 09, 396, 398. See also International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) project
ICH Guidelines, 392
ICH Q5E, 410
ICH Q7A, 388
ICH Q10, 387, 388
Icterus gravis, 217
Identification, of IVIG preparations, 192
IgG–Fc receptor interactions, 208. See also Immunoglobulin G (IgG)
IgG fragments, accompanying IVIG preparations, 197, 198
IgG production process, 199, 200
IgG purification process, 187
Immobile antibodies, 33
Immune neutralizing antibodies, solvent detergent treatment and, 348
Immune response, 57, 106
“Innune sera,” 207
Immune serum globulin, 16, 214
Immune suppressive action, ceruloplasmin and, 341
Immune thrombocytopenic purpura
(PTP), 218–221. See also Thrombotic thrombocytopenic purpura (TTP)
Immune tolerance, to FVIII, 37, 38
Immunization, passive, 7
Immunodeficiencies, secondary, 185
Immunogenicity, 89, 251, 406
Immunohistochemical techniques, 316
Immunoglobulin protein removal, 187
Immunoglobulin production, 12, 21, 22
Immunoglobulin preparations, 7
in previously treated proteins, 37
in previously untreated patients, 37
Immunoglobulin preparations, 7
Immunoglobulin therapy, 210
Immunoglobulin intoxication, 37
Immunoglobulin A (IgA), IVIG preparations and, 193
Immunoglobulin G (IgG), See also IgG
characteristics of, 207
demand for, 462
hyperimmune, 207–216
recovery of, 7
Immunoglobulin G loss, 1868
Immunoglobulin molecule integrity of, 191
structure of, 20
Immunoglobulin preparations, 7
procoagulant activity in, 199
Immunoglobulin production, 12, 21, 22
Immunoglobulin products, 199
treatment of, 364
Immunoglobulin protein removal, 187
Immunohistochemical techniques, 316
Immunological incompatibility, 6
Immunomodulatory properties, of albumin, 164
Immunoprotection, ceruloplasmin and, 341
Immunotherapy
passive, 207, 209, 210
Imported plasma products, 18
Impurities
accompanying IVIG preparations, 194, 197, 198
control of, 409
Independent medical education (IME), 418
India, plasma fractionation in, 19, 20
Industrialized countries, as strategic partners, 465
Industrial-scale alpha1-PI purification, 231–237
Industry consolidation, overview of, 466
Industry standards, 385
Infection, caused by inflammation, 325
Infectious agents, in blood, 361
Infectious diseases, convalescent serum for, 209
Infectious inflammatory diseases, ceruloplasmin and, 342
Inflammation
atherosclerosis and, 275
infection caused by, 325
Inflammatory cascade, 330. See also Clotting cascade
Infusion solutions, 8
Inhalable alpha1-PI, 238
Inhibitor development, 89
in hemophilia A, 57
Inhibitor dogs, 55
Inhibitor patients, controlled bleeding in, 52
Inhibitor plasma, clotting time of, 53
Inhibitor rabbits, 55, 56
Inhibitors
FVIII-inactivating, 37, 38
in previously treated proteins, 37
in previously untreated patients, 37
Inhibitory alloantibodies, 57
Inhibitory antibodies, 37, 57, 73, 74
Inhibitory factors, 66
Innovation, industry success and, 468
Innovative plant biotechnology, future of, 295
Innovative products, development of, 462
Installation qualification (IQ), 391
Institut Mérieux, 11
Integrated medical action plan (IMAP), 420
Interleukin 6 (IL-6), 326
Intermittent flow centrifugation, 4
Internal audits, 399
Internal communication/coordination, 420, 421
International Conference on
Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) project, 385, 429. See also ICH entries
International normalized ratio (INR), 74
International Organization for Standardization (ISO), 386
International Plasma Fractionation Association (IPFA), 467
International Quality Plasma Program (QPP), 424, 427
International Society for Pharmaceutical Engineering (ISPE), 392, 393
International suppliers, 398
Intoxication, ceruloplasmin and, 341
Intracellular Factor XIII (cFXIII), 102.
Intervention, ceruloplasmin and, 341
Intravenous lys-plasminogen, 316, 317
Intravenous immunoglobulin (IVIG), 17, 20, 185, 219–221. See also IVIG entries
global sales of, 462
safety of, 220, 221
Intravenous immunoglobulin G (IgG), from human plasma, 185–205
Intravenous immunoglobulin products, sales of, 451–453
Intravenous lys-plasminogen, 316, 317
Intrinsic clotting pathway, 82
Inventory Hold standard, 427, 428
Investigations, actions related to, 395
Investigator-initiated trials (IITs), 418, 419
In vitro cholesterol efflux, 294
In vitro efficacy studies, 264, 265
In vitro studies, 53–55
In vivo efficacy studies, 265, 266
In vivo recovery (ivr) concept, 88, 89
In vivo studies, 55–57
Ion exchange chromatographic fractionation technology, 11
Ion exchange chromatographic steps, 188
Ion exchange chromatography (IEC), 33, 34, 213, 214
in albumin manufacture, 165
in plasma fractionation, 441
in vWF purification, 44, 45
Ion exchange/gel filtration combination, in vWF purification, 45
Iranian Blood Transfusion Organization, 21, 458
Iron-binding proteins, 301, 306
Iron depositions, heart damage and, 301
Iron metabolism, regulation of, 306, 307
Irradiation, for virus inactivation, 364
Iron-binding proteins, 301, 306
Ischemia, C1-inhibitor and, 250
Ischemic heart disease, 273
Israel, plasma fractionation facilities
Intracranial hemorrhages, 219
Intravenous immunoglobulin (IVIG), 17, 301
Intravenous hyperimmune products, 207
Intravenous immunoglobulin concentrates, quality criteria
for, 185, 186. See also Intravenous immunoglobulin (IVIG)
IVIG preparations
aggregate formation in, 195
anticoagulant activity of, 192, 193
Fc function in, 195
formation of, 198
hemagglutinins and, 193
identification of, 192
immunoglobulin A and, 193
molecular size distribution of, 192
osmolarity of, 192
pH of, 192
plasma proteins accompanying, 197, 198
prekallikrein activator in, 193
process-related impurities in, 194
protein composition of, 192
purification schemes for, 199
pyrogens and endotoxins in, 193, 194
safety and adverse events related to, 198, 199
sterility of, 193
subclass distribution in, 194, 195
total proteins of, 192
visual appearance of, 191, 192
IVIG products, differences among, 199
IVIG quality parameters, 191–195
IVIG-related thrombotic events, 199
IVIG solutions, heat treatment of, 190
IV pastes, See Cohn Fraction IV-1, 4
pastes
Janeway, Charles, 6
Japan
blood transfusion in, 17
haptoglobin studies in, 331
plasma fractionation in, 17, 18
Japanese monograph, 87, 88
Japanese Red Cross (JRC), 14, 17
Jesse, Jens, xi, 383
Joint bleeding, 58
Jorquera, Juan Ignacio, xi, 81
JTT-705, 273
Kaar, Waltraud, xii, 185
Kabi, 11
Kaketsuken, 18
Kalbitzer, 251
Kalilkrein, 242
hereditary angioedema and, 248
Kamada Ltd., 20, 238
Kamada Ltd Glassia™ purification process, 235–237
KASKADIL, 71
Kedrion, 15, 461
Kedrion clinical development program, 317, 318
Kedrion evaluation of plasminogen product, 318
Kedron plasminogen case study, 317
Kedron plasminogen manufacturing process, 311, 314, 315
Kendrick, D. B., 6
Kernicterus, 217
Key opinion leaders (KOLs), relationships with, 418
Key regulatory standards, compliance with, 416
Kininogen, 93, 94
KIOVIG process steps, 189
Kirschbaum, Nancy, xii, 403
Kistler–Nitschmann fractionation process, 12, 186, 213, 327
Cohn fractionation process vs., 165
Kistler–Nitschmann fractionation method, 12, 186, 213, 327
Koch, John, xii, 97
Kolb, Hans, 295
Koenderman, Anky, xii, 241, 301
Kogenate®, 36
Korean Red Cross (KRC), 18, 19
Kramer, Christine, xii, 241
Krammer, Hans, 18
Krammer, Hans, 6
Kringle domains, 259
in plasminogen, 311, 312
Labeling, for source plasma, 426
Laboratoire Francaise du Fractionnement et des Biotechnologies (LFB) concentrate, 96
Laboratorios Grifols, 10, 21. See also Grifols entries
growth of, 16
internationalization of, 15
Laboratory deviations, 396
Laboratory-scale alpha1-PI purification, 229–231
Laboratory-scale purification methods, 229–231
Landsiefer, Karl, 3
Large buffer volumes, in plasma fractionation, 442
Large-scale manufacturing, of transferrin, 303, 304
“Last litter economics,” 452
Law on Securing a Stable Supply of Safe Blood Products and the Revised Pharmaceutical Affairs Law (Blood Law) of 2003, 18
Lebing, Wytold, xii, 227
Lecithin-cholesterol acyltransferase (LCAT), 273, 274, 284
Lys-plasmin structure, 312
Macrophages, 324
Maillard reaction, 192
Major inflammatory events, 152
“Make-or-buy” decisions, 458
Management leadership, 429
Mannan binding lectin-associated protease (MASP), 243. See also MASP-2
Marketing failures, 446
Marketing processes for apolipoprotein AII (dilano) optimization of, 66
Manufacturing technologies, new, 445, 446
Marcucci, Paolo, xii, 461
Marcucci Group, 15
Marketing departments, independence from Medical Affairs, 413
Market performance, 462–464
Marx, Gerard, xii, 117
MASP-2, inactivation mechanism of, 244. See also Mannan binding lectin-associated protease (MASP)
Massachusetts Biologic Laboratories (MBL), 9
Massive bleeding, PCCs to stop, 73
Master Batch Record, 444
Matrix-assisted laser-desorption ionization (MALDI) analysis, 263
Medical Affairs departments, 413, 414
diverse functions of, 415–420
emerging role of, 413–415
globalization of, 414
goals of, 415
IIT issues and, 419
independence from Marketing, 413
independent medical education and, 418
key bridging function of, 419
partnership with R&D and Marketing, 414
Phase 4 studies and, 420
strategic planning and, 417
“Medical Affairs: Effective Global Resource Allocation,” 415, 416
Medical Affairs partnership, 416
Medical Affairs personnel, 421
Medical Affairs policy, 418
Medical Affairs reporting structure, changes in, 415
Medical and Scientific Advisory Council (MASAC), 58
Medical information centers, 417, 418
effectively managed, 418
Medical science liaisons (MSLs), role of, 418
Meeting briefing document, 405
Meeting questions, 405
Membrane attack complex (MAC), 243
Membrane chromatography, 445, 446
Membranes, columns vs., 445, 446
Mercaptoalbumin (MA), 171
Messenger RNA (mRNA) splicing, 95
Metal-chelating chromatography, 85
Michaelis complex, 244
Microbiological purity, 194
Microfiltration, in plasma fractionation, 442
Microfluidic devices, 119
Microgen, CP manufacture by, 339, 340
Middle East, fractionation in, 20, 21
Mimetic ligand affinity, 97
Minimal concentration of fibrinogen, 118
Minimum Requirements for Biological Products 2006, 87, 88
Minipool testing, 428
“Missense” mutation, 95
“Mixed mode” resins, in plasma fractionation, 441
Model viruses, 362, 363
Molecular adsorbent recirculating system (MARS), 175
Molecular integrity, 107
Molecular size distribution for albumin, 171
of IVIG preparations, 192
Molecules, binding to fibrinogen, 119, 120
NAT testing, 427, 428, 453.
National transfusion infrastructures, 4, 5
National policies, 13, 14
National Plasma Fractionation Center, 19, 20
National policies, 13, 14
National transfusion infrastructures, 4, 5
NAT testing, 427, 428, 453. See also Nucleic acid-based testing (NAT)
Negative column chromatography, 188
Negatively charged platelet microparticles, removal of, 351, 352
Neisser-Svae, Andrea, xii, 345
neoFib, 123
Netherlands Red Cross, 14
Neurodegenerative illnesses, 369
Neutralizing antibodies, 191
Neutrophil elastase, 228
New manufacturing technologies, 445, 446
New York Blood Center (NYBC), 9
New York Blood Transfusion Betterment Association, 10
Nexin 2, 95
N-glycosylation sites, 93
Niche products, 214
Nitric oxide (NO), albumin as carrier
for, 164. See also NO signaling
Nitschmann, H., 12
Nomenclature, plasma-related, 424
Noncholate-based methods, 292
Nonclinical pharmacology/toxicology, 406
Nonenveloped viruses (NEVs), 72, 73, 190, 191
solvent detergent treatment and, 348
Nongovernmental organizations (NGOs), 454
Noninhibitory antibodies, 57
Nonreducing SDS-PAGE, 329
Nonremunerated plasma, 384
Noninhibitory antibodies, 57
Nonreducing SDS-PAGE, 329
Nonremunerated plasma, 384
“Nonsense” mutation, 95
No observed adverse effect level
(NAEEL), 266
“Norfolk Incident,” 6
Normalized water permeability (NWP), 168
North Africa, fractionation in, 20, 21
North America
immunoglobulin consumption in, 186
plasma collection in, 21
plasma fractionation industry in,
7–10
North American market, 463, 464
NO signaling, 326. See also Nitric oxide (NO)
Not-for-profit fractionation, in Europe,
11–13
Not-for-profit fractionators, processing capacity of, 14
Not-for-profit manufacturers, 21
Not-for-profit sector, 461
consolidation in, 14
Novel viruses, 65
Novokhatny, Valery, xii, 259
Nucleic acid-based testing (NAT), 72, 361–363, 384. See also NAT
testing
Nyikofuk, Cory, xii, 283
Octagam batches, 197
Octagam process steps, 190
Octanoic (caprylic) acid fractionation, 187
Octanoic (caprylic) acid treatment, 190
Octapharma AG, 13–15, 190, 451, 453,
461
growth of, 16
as solvent/detergent plasma producer,
345, 346, 348
Octaplex®. 345, 346
biochemical characterization of, 351
Octaplas(LG), 347, 351, 352, 354
anaphylactoid reaction rate for, 352
biochemical profile of, 350
clinical efficacy of, 353
indications for, 353
manufacturing of, 346
single-donor FFP vs., 352, 353
virus neutralization and prior removal from, 349
Octaplex®. 70, 71
Octaplex® manufacturing process, 72
Oilbody (OB) biogenesis, 290
Okemefuna, Azuabuike, xii, 321
Oliver, Percy, 4
Omni Bio Pharmaceuticals, Inc., 238
On-demand treatment, 58
Oniplas, 353
OOS handling system, main requirements for, 395. See also Out of specification (OOS) occurrences
OOS results, 396
Operational costs, of a developing-nation plasma fractionation facility, 456, 457
Operation qualification (OQ), 391
Operations, in the production process, 444, 445
Opsonization, 208
Orphan drugs, 238, 468
Orphan drug system, 101
Osmolality, of IVIG preparations, 192
Outcomes research, 419
Out of specification (OOS) occurrences, 393–395. See also OOS entries
Over, Jan, xii, 301
Oxidation, of hemoglobin, 326
Oxidation damage, 326
Oxidative process reduction, ceruloplasmin and, 341
Oxidative stress, albumin and, 164
Oxidized LDL, 326. See also Low-density lipoprotein (LDL)
Paiz, Antonio, xii, 81
Paid blood donors, 12
in India, 19
Pancreatitis, C1-inhibitor and, 250
Parasites, pathogen transmission via, 347
Parkkinen, Jaakko, xii, 301
Partial prothrombinase complex, 57
Partial thromboplastin time (PTT) test, 118
Parvovirus B19 (B19V), 72, 191.
See also B19 NAT
Parvoviruses, 328
Passive antibody administration, 210
INDEX 487

Passive immunization, 7 protective factor of, 349
Passive immunotherapy, 207 with convalescent plasma, 209, 210 hyperimmune, 209, 210 Pasteurization, 35, 104, 190, 247 of albumin, 165, 166 of ATIII, 150 enhanced, 176, 177 in plasma fractionation, 442, 443 for virus inactivation, 364 Past hyperimmune initiatives, 214 Pathogen inactivation/removal procedures, product safety via, 150, 151 Pathogen reduction, 65 Pathogen removal, 354 Pathogen safety, ix, 65, 72, 73, 233, 251, 263, 264 in plasma fractionation industry, 231 solvent/detergent plasma and, 346, 347 Pathogen safety-related measures, 86, 87 Pathogen transmission, risk of, 106 Patients, with FVIII-inactivating inhibitors, 37, 38 PCC capture, 83, 84. See also Prothrombin complex concentrates (PCCs) PCC dosage optimization, 74 PCC factor deficiencies, 73 PCC factor domain structures, 68 PCC factor function, 67 PCC factors, 74 PCC manufacturing procedures, 71 PCC manufacturing process, state-of-the-art, 70, 72 PCC packaging, 72 PCC product characteristics, 66 PCC production processes, state-of-the-art, 73 PCC reactions, 75 PCC starting material, 83 PCC starting material isolation, facility requirements for, 87 Peeling. See Plasma peeling process Peer-to-peer scientific exchange, with physicians, 415 Performance qualification (PQ), 391 Peripheral arterial occlusion (PAO), 268 Peripheral vascular disease, 277 Perry, David, xii, 413 Persistent ITP, xii. See also Immune thrombocytopenic purpura (ITP) Petteway, Stephen, Jr., xii, 259 pFXIII tetramer, 102. See also Factor XIII (FXIII)

Plasma-derived (pd) FII-FXa complex, 56. See also Factor II (FII, prothrombin); Factor Xa (FXa); Prothrombin entries
Plasma-derived coagulation products, viral contamination of, 36
Plasma-derived FVIIa, 56. See also Factor VIIa (FVIIa)
Plasma-derived FVIII, 55. See also Factor VIII (FVIII)
Plasma-derived hyperimmune products, 43, 82, 83
Plasma-derived hepatitis B vaccine, 9
Plasma-derived HDL, 273–282
Plasma-derived Factor XIII (FXIII) activity, 102. See also Factor XIII (FXIII)
Plasma for fractionation, 434
“Plasma for Great Britain Project,” 10
Plasma for stable products, 432
Plasma protein therapeutics, future of, 410
Plasma Protein Therapeutics Association (PPTA), 385, 398, 424, 426, 457, 467. See also PPTA voluntary standards
Plasma protein therapeutics production/commercialization, regulatory activities associated with, 403–411
Plasma purification, 440, 441
Plasma quarantine, 428
Plasma purine, 139, 140, 262
Plasminogen, 139, 140, 262, 263
Plasmin manufacturing process, 262, 263
Plasmin inhibitors, 141
Plasmin formulation, low pH, 261, 262
Plasmin efficacy, relationship to safety, 268, density
Plasmin efficacy, relationship to safety, 268, density
Plasmin formulation, low pH, 261, 262
Plasmin inhibitors, 141
activity of, 350
Plasmin manufacturing process, 262, 263
Plasminogen, 139, 140, 262
activation of, 259
Plasminogen activators (PAs), 261
Plasminogen activators (PAs), 261
failure of, 261
Plasminogen concentrate, 311, 317
Plasminogen concentrate preparation, key development in, 313, 314
Plasminogen deficiencies, 311, 315, 316
Plasminogen eye drops case studies, 317
Plasminogen–plasmin system, 260
Plasminogen process, 263
Plasminogen products future of, 318
Kedrion evaluation of, 318
Plasminogen purification, by affinity chromatography, 314, 315
Plasminogen reduction, 141
Plasminogen synthesis, 311, 312
Plasmin process, 263
Plasmin products, characterization of, 263
Plasmin Revascularization for the Ischemic Lower Extremity (PRIORITY) trial, 268
Plasmin storage, 260
Plasmin structures, 260
Plasmin therapeutic index, 269
Plasmin tolerance, 266
PLAS + SD (S/D-treated plasma), 9
Plastic bag blood collection system, 4
Plate filter designs, 168
Platelet adhesion, vWF protein and, 42
Platelet agglutination, 43
Platelet counts, 220
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Platelet Factor XI, 94, 95.
Prion removal, 349, 350
Prions, inactivation of, 73
Privigen manufacturing process, 187, 188
PRNP gene, 376
PRNP genotypes, 373
ProApoAI proprotein, 285
Procedures, in the production process, 444, 445
Process analytical technology (PAT), 387, 390
Process charting, 390, 391
Process comparability strategy, 409
Processes, control of, 406, 407
Process-induced aggregation, 195
Process quality, 386
Process-related impurities, in IVIG preparations, 194
Process technology development, in the plasma fractionation industry, 167, 168
Procoagulant activity, in immunoglobulin preparations, 199
Procoagulant process, maintaining, 60
Procoagulants, 59
Proconvertin, 65
Product characterization, 408
Product development, 112
Product quality, 408
Product life cycle management, quality by design in, 407, 408
Product range, for the developing world, 455
Products, control of, 406, 407
Product safety, 398, 399
ensuring, 35, 36
ensuring by pathogen inactivation/removal, 150, 151
Product testing, 263
PRO-FEIBA® study, 58
Profilnine SD, 71
Project management, 404
Prolastin®, 227, 233
Prolastin-C purification process, 234, 235, 236, 237
Prolastin purification process, 232, 233, 236
Prophylactic regimens, C1-inhibitor in, 250
Prophylactic therapy, with FVIII and FIX, 58
Proplex-T, 71
Protalix, 290
Protease inhibition, 148
Protein augmentation therapy, with αγ-PL, 229
Protein C, 70, 75, 148
biochemical characteristics of, 68
HDL and, 275
Protein composition, of IVIG preparations, 192
Protein C pathway, 67
Protein formulation, 328
Protein multimerization, 41
“Protein only” hypothesis, 370
Protein S, 69, 70, 75
biochemical characteristics of, 68
HDL and, 275
Protein Z, 69, 70, 75
Protein Z-dependent protease inhibitor, 107
Proteolytic processing, in Golgi apparatus, 41
ProthoRAAS, 71
Prothrombin, 65, 139, See also Factor II (FII, prothrombin)
FXa and, 59
role of, 53–55
Prothrombinase complex, 59
Prothrombin complex (PCC), 65–79, 142, 439
characteristics of, 70–72
Prothrombin complex concentrates (PCCs), 49, 51–53, 65, 110, 353, 439
as bypassing agents, 75, 76
for bypassing therapy, 52
clinical issues related to, 73–75
clinical trials with, 52
clinical use of, 66
effectiveness of, 52
Factor X in, 108
freeze-dried, 70
heparin and antithrombin in, 75
history of, 65, 66
importance of, 66
in intensive care medicine, 75
manufacturing of, 69, 70
quality of, 66
safety considerations related to, 74, 75
to stop massive bleeding, 73
therapeutic indications for, 66
thrombotic events with early generation, 66
Prothrombin complex zymogens, roles of, 51–53. See also Prothrombin zymogen
Prothrombinex-VF, 71
Prothrombin–FXa complex, 54, 58, 59
pharmacokinetic properties of, 57
potency of, 55, 56
results obtained with, 57
Prothrombin time (PT), 74
Prothrombin time (PT) test, 111, 112, 118
Prothrombin zymogen, role of, 59
Prothrombotic reactions, 74, 75
Prothromplex-T, 71
PrP protein, 269, 370. See also Prion protein (PrP)
PrP30® protein, 369, 370, 371, 372, 373, 375, 376
Pseudomembranous disease, 315
Pseudomembranes, recurrence of, 317
Publication planning/execution, 417
Public health, regulatory authority and, 410
Public/private collection systems, 467
Pulmonary diseases, 228
Pure FXa, 54
Purification, in plasma fractionation, 440, 441
Purification concepts, 186–189
Purification methods for αγ-PL, 229–231
in development, 38
Purification principles, 185
Purification schemes/techniques, 142
for IVIG preparations, 199
Purification technologies, 33–35
development of, 46
Purified FXa, 54
Purification, in plasma fractionation, 440, 441
Purification methods, 186–189
Purification methods for αγ-PL, 229–231
in development, 38
Purification principles, 185
Purification schemes/techniques, 142
for IVIG preparations, 199
Purification technologies, 33–35
development of, 46
Purified FVIII, production methods for, 33–35. See also Factor VIII (FVIII)
Purified Factor IX, European and Japanese requirements for, 87, 88
Purified plasma-derived porcine FVIII, 37
Purified prionin, 53
Pyrogens, in IVIG preparations, 193, 194
Pyrogen testing, 194
QAE-Sephadex®: 70
QA system, 397. See also Quality assurance system
QC laboratories, 388, 389. See also Quality control (QC)
“Quaking-induced conversion” (QuIC), 376
Qualification, 391–393
Qualified donors, 361
Qualified Donor standard, 427
Quality Agreement, 399
Quality assurance (QA), 383, 395, 397
Quality assurance requirements, in plasma product manufacture, 383–401
Quality assurance system, 386, 387.
See also QA system; Quality systems responsibilities of, 386
Quality by design (QbD), 387, 389, 407, 410
applying to product life cycle management, 407, 408
Quality control (QC), 386, 387. See also QC laboratories
Quality maintenance, 444, 445
Quality management reviews, 387
Quality Risk Management guideline, 398
Quality Standards of Excellence, Assurance and Leadership (QSEA), 424
Quality systems, 429. See also Quality assurance system interfaces to, 399
Quality Systems Regulation, 403
Quarantine, of plasma, 428
Quarantine plasma, 433
Quarantine residual plasma, 433
Quick, J., 74
Quick value, 74
Rabbit stroke model, 265, 266
Rabies immunoglobulin products, 20
“Radial flow” type columns, in plasma fractionation, 442
Rare diseases, 101, 462, 463
Ravdin, Isador, 6, 7
Reactive nitrogen species (RNS), 164
Reactive oxygen species (ROS), 164, 326
Rebbeor, James, xii, 259
Recombinant activated Factor VII (rFVIIa), 96
Recombinant ApoA-I preparations, 274
Recombinant apolipoprotein A1M1anaro, manufacturing large quantities of, 289
Recombinant DNA products, 17
Recombinant-DNA technology, 250, 451
Recombinant (r) FII-FXa complex, 56.
See also Factor II (FII, prothrombin); Factor Xa (FXa); Recombinant prothrombin–FXa complex
Recombinant FVIIa (rFVIIa), 65
Recombinant FVIIa (rFVIIa) treatment, 57
response to, 56
Recombinant Factor VIII, 55. See also Recombinant Factor VIII entries
Recombinant FXIII-A (rFXIII-A), 105, 106
Red Cross transfusion services, 11, 12
Redox properties, of albumin, 164
Reduced vitamin K, 81
Reducing SDS-PAGE, 329
Reduction studies with endogenous blood infectivity, 375
with exogenous infectivity, 375, 376
ReFacto®, 37
ReFactoR®, 36
Regional fractionation centers, 11
Regulations plasma-related, 385
standardized, 414
Regulatory affairs (RA) departments, role of, 403, 404
Regulatory affairs (RA) professionals, 403, 404
Regulatory agencies, role in biopharmaceutical development/commercialization, 404, 405
Regulatory application, preparation of, 407
Regulatory authorities interaction with, 404
public health and, 410
Regulatory compliance, 112
Regulatory environment changes in, 413
of plasma-derived products, 383–385
Regulatory processes, differences among, 403
Regulatory standards, compliance with, 416
“Reischauer Affair,” 17
Recombinant (r) FII-FXa complex, 56.
See also Factor II (FII, prothrombin); Factor Xa (FXa); Recombinant prothrombin–FXa complex
Recombinant FVIIa (rFVIIa), 65
Recombinant FVIIa (rFVIIa) treatment, 57
response to, 56
Recombinant Factor VIII, 55. See also Recombinant Factor VIII entries
Recombinant FXIII-A (rFXIII-A), 105, 106
Recombinant Factor VIII entries
Recombinant FIX concentrate, 89. See also Recombinant Factor IX entries
Recombinant FXIII-A (rFXIII-A), 105, 106
Recombinant fibrin glues, 144
Recombinant hepatitis B vaccine, 209
Recombinant human alpha1-PI, 237
Recombinant human antithrombin III (rhATIII), 151
Recombinant human serum albumin (rHSA), development of, 177, 178
Recombinant plasma proteins, 36
human plasma proteins vs., 467, 468
Recombinant polyclonal antibodies, 467
Recombinant products, 251, 467
Recombinant protein therapeutics, transgenically produced, 38
Recombinant prothrombin–FXa complex, 54. See also Recombinant (r) FII-FXa complex
Recombinant techniques, 112
Recombinant technology, 467
Recombinant transferrin products, 304, 305
Recombinant vWF, plasma- and albumin-free, 46
Recombinant®: 36
Reconstituted HDL disks, 277
Reconstituted HDL infusions, effects of, 278
Reconstituted HDL preparations, 274
tolerability of, 277
Reconstituted HDL therapies, 295
Recovered plasma, 423, 424, 430
Recovered-plasma products, 195, 196
Red blood cells (RBCs), 120, 326
vCJD transfusion transmission risk and, 373
Red Cross, European governments and, 11–13. See also American Red Cross (ARC); Australian Red Cross; Canadian Red Cross; Central Laboratory of the Netherlands Red Cross (CLB); Deutsches Rotes Kreuz (DRK) Blutspendedienst Nordrhein-Westfalen; Finnish Red Cross entries; German Red Cross entries; Israeli Red Cross; Japanese Red Cross (JRC); Korean Red Cross (KRC); Netherlands Red Cross; Swiss Red Cross
Red Cross fractionation services, 11, 12
Redox properties, of albumin, 164
Reduced vitamin K, 81
Reducing SDS-PAGE, 329
Reduction studies with endogenous blood infectivity, 375
with exogenous infectivity, 375, 376
ReFacto®, 37
ReFactoR®, 36
Regional fractionation centers, 11
Regulations plasma-related, 385
standardized, 414
Regulatory affairs (RA) departments, role of, 403, 404
Regulatory affairs (RA) professionals, 403, 404
Regulatory agencies, role in biopharmaceutical development/commercialization, 404, 405
Regulatory application, preparation of, 407
Regulatory authorities interaction with, 404
public health and, 410
Regulatory compliance, 112
Regulatory environment changes in, 413
of plasma-derived products, 383–385
Regulatory processes, differences among, 403
Regulatory standards, compliance with, 416
“Reischauer Affair,” 17
Safety. See also Blood safety programs; Pathogen safety entries; Product safety; Virus safety; Virus safety system of blood products, 189, 190 of coagulation products, 38 ensuring by pathogen inactivation/removal, 150, 151 Factor X-related, 110, 111 of FEIBA® products, 57, 58 of human albumin, 176–178 of IVIG preparations, 198, 199 of PCCs, 74, 75 of plasma, 86, 96 of plasma-derived fibrin glues, 144 of plasma-derived products, 35, 406 of plasma products, 106 plasmin efficacy relationship to, 268, 269 preclinical evidence of, 264–267 of Rh (D) immunoglobulin and IVIG, 220, 221 of solvent/detergent plasma, 351–353 viral, 86, 96 Safety assessments, 267 Safety pharmacology studies, plasmin-related, 266, 267 Safflower-derived apolipoprotein AI Milanos, 290–292 biological activity of, 292–295 preclinical efficacy of, 294 Saline versus Albumin Fluid Evaluation (SAFE) study, 172, 173 Salvaged plasma, 433 Sanquin-CAF-DCF organization, 14 Sanquin Plasma Products, 304 SARS-Corona virus, 363. See also Severe acute respiratory syndrome (SARS) Saturated ammonium sulfate (SAS), 244 Saudi Arabia (KSA), fractionation facility in, 20, 21 Saudi Arabian Plasma Group (SAPG), 21 Saudi Pharmaceutical and Appliances Corporation (SPIMACO), 20, 21 Schultz–Heimburger purification method, 230 Schwarz, Hans Peter, xii, 49 Scientific/medical knowledge, disseminating, 421. See also Research and development (R&D) Scope of a project, 454 Scott, Dorothy, xii, 369 Scottish National Blood Transfusion Service (SNBTS), 11, 20 Scrapie, atypical forms of, 376 Scuderi, Philip, xii, 259 S/D plasma, 433. See also Solvent detergent (S/D) plasma S/D plasma production methods, 346 S/D plasma products, coagulation factors and inhibitors in, 350 S/D reagents, 348 Secondary immunodeficiencies, 185 Secondary ITP, 219. See also Immune thrombocytopenic purpura (ITP) Seed-based expression, in plants, 289–295 Seed overexpression, 290 Self-sufficiency, high-purity Factor IX and, 89, 90 Self-sufficiency plan, 21 Self-sufficiency policies, 13, 14, 16, 17, 18 SemBioSys Genetics Inc., 290, 295 SemBioSys production platform, 290 Separation resins, 33 Sepharose® beads (SBs), 120, 122, 125. See also DEAEE-Sepharose® FF; ECH-Lysine Sepharose resin; Heparin-Sepharose® entries; Hexyl-Sepharose® Sepsis albumin and, 176 C1-inhibitor and, 249, 250 Sequential ethanol precipitation, 440 Sequential precipitation, 437 Serine protease inhibitors ("serpins"), 227, 228, 241. See also Serpin entries Serious adverse events (SAEs), 268 Serpin C1-inhibitor, 244 Serpin C1-inhibitor domain, 3D models of, 241, 242 SERPING1 gene, 241 Serum, 3. See also Blood entries; Plasma entries equine, 6 Serum albumin, clinical issues related to, 171–176 Serum Institute of India, 19 Serum levels, albumin and, 171, 172 Serum therapy, 207, 214 Severe acute respiratory syndrome (SARS), convalescent plasma treatment of, 209, 210. See also SARS-Corona virus Severe ITP, 219. See also Immune thrombocytopenic purpura (ITP) Shearer process, 232 Shen, Yin, xii, 283 Short consensus report (SCR) domain, in haptoglobin, 323 Short Supply Agreement, 406 Sinclair, Christopher, xii, 207, 217 Single-donor FFP, Octaplas(LG) vs., 352, 353. See also Fresh frozen plasma (FFP)
Index

493

INDEX

Sporadic CJD (sCJD), 369, 371.

Spontaneous bleeding episodes, 58

Spongiform encephalitis/

Spiking preparations, 375

Spiked viruses, inactivation of, 364

Specific activity (SA), 83, 84

Spanish flu H1N1 pandemic, 209

South-East Asia, plasma fractionation
departments and, 417

South African Blood Transfusion Service
Source plasma regulations, 424, 430

Source plasma collection, anticoagulant
solution for, 426

Source plasma, 21, 424, 430

donation of, 361

labeling for, 426

Source plasma centers, 427

Source plasma collection, anticoagulant
solution for, 426

Source plasma regulations, 424

South African Blood Transfusion Service
(SABTS), 13, 14

South American market, 463

South-East Asia, plasma fractionation
in, 18, 19

Spanish flu H1N1 pandemic, 209

Specific activity (SA), 83, 84

Spiked infectivity, reducing, 375, 376

Spiked viruses, inactivation of, 364

Spiking preparations, 375

Splenectomy, 219

Spongiform encephalitis/
encephalopathy, 35

Spontaneous bleeding episodes, 58

Sporadic CJD (sCJD), 369, 371. See also
Human sCJD; Variant Creutzfeldt-Jakob disease entries
Spray-dried fibrinogen/thrombin, 143

SRBI receptor, 292, 293

“Standardized” filtered blood, 10

Standardized regulations, 414

Standard operating procedures (SOPs),
388, 389, 399, 429, 444

Standard procedures, violation of,
393–395

Standard purification principles, 185

Standards, in donor screening, 426, 427

Starling’s Law, 161

Starting material plasma, composition
of, 200

State-of-the-art PCC manufacturing
process, 70, 72. See also
Prothrombin complex concentrates
(PCCs)

State-of-the-art PCC production
processes, 73

Statin therapy, 273

Statistical data/charts, 329

Steam in place (SIP) centrifuge
design, 167

Stem cell harvesting, 125

Sterile filtration, solvent/detergent plasma
and, 347

Sterile vacuum-type blood collection
unit, 9

Sterility, of IVIG preparations, 193

Steroid hormones, albumin binding
to, 163

S-TIM4 vapor heat treatment, 49

Stokes, Joseph, 7

Strategic National Stockpile (SNS),
210–212

Strategic planning, Medical Affairs
departments and, 417

Streptokinase, 260

Stroke, 268

Stuart–Prower factor, 65

Subclass distribution, in IVIG
175, 176

Substantial regulations, 414

Substitution therapy, 306

for Factor X deficiency, 110

Substrate concentrations, increasing, 59

Sudlow sites, 161

Suicide inhibitor, 243

Summary of product characteristics
(SPC), 66

SODs, 338

Supplier audit program, 399

Supplier audits/inspections, 398

Suppliers, audits/inspections of, 398.
See also Plasma suppliers

Surgical glues, 137

Sustainability, 16, 17

Swae, Tor-Einar, xii, 345

Svedberg, Theodore, 6

Swine flu, convalescent plasma treatment
of, 210

Swiss Red Cross, 20

Sympress™ expression system, 221

Synthetic colloids, 172

Synthetic plasma expanders, 172

Talecris Biotherapeutics, Inc., 15, 21,
234, 235, 236, 262, 451, 461, 466
growth of, 16

Target antigen binding, 208

Task Force on Clinical Use of FIX
Concentrates, 52

Technology types, for the developing
world, 455

Temporary hemophilia, 55

Tenascins, 122

“Tenase” complex, 81, 82

ter Hart, Henkie, xii, 301

Terminal incubation, in albumin
manufacture, 166

Terminal nanofiltration, 87

TF/Factor VIIa complex, 81

β-Thalassemia, 307

Thawing process, in plasma protein
collection, 438, 439

Therapeutic C1-inhibitor products,
247, 248

Therapeutic exchange plasma (TEP),
433

Therapeutic FVIII production,
development strategies for, 38.
See also Factor VIII (FVIII)

Therapeutic Factor X concentrate, 108

manufacture of, 108–110

Therapeutic Factor XIII concentrate,
manufacture of, 103

Therapeutic plasma exchange (tPEx),
175, 176

Therapeutic plasma proteins, availability
of, 465

Therapeutic products, plasma-derived,
461

Therapeutic proteins
extraction and purification of, 290
plasma as a source of, 101
from transgenic plants, 295

Therapeutics, control and oversight of
critical, 446

Thiol, in albumin, 171

Thrombin, 139

FXI activation by, 94

spray-dried, 143

Thrombin activatable fibrinolysis
inhibitor (TAFI), 95

Thrombin activation, 42, 43

fibrinogen polymerization induced
by, 118, 119
Thrombin component, 137
production of, 142, 143
Thrombin concentration, 81
Thrombin generation, 57, 59
Thrombin generation assay, 53
Thrombin generation curves, 53, 54
Thrombin inhibition, heparin and, 139
Thrombin inhibitors, 141
Thrombin polypeptide chains, 139
Thrombin regulation, 147
Thrombin solutions, for hemostasis, 142, 143
Thrombocytopenias, 218, 219
Thromboembolic events, 74, 199
Thromboembolic risk factors, 75
Thromboembolism, risk of, 176
Thrombogenicity, 84, 106
Thrombogenicity risks, 89
Thrombogenicity tests, 111
Thrombogenic material, separating, 110
Thrombolysis therapy, 261
Thrombolytics, acid-stabilized plasmin
Thrombolysis treatment testing, 266
Thrombolysis (TTvCJD) infections, 373
Thrombolytic agents
limitations of, 261
plasma-derived plasmin as, 268
Thrombolytic conditions, human plasmin for, 266
Thrombolytics, acid-stabilized plasmin as, 259–271
Thrombosis, 73, 221, 351
Thrombosis model system, 264, 265
Thrombotic events, 58, 96
with early generation PCCs, 66
Thrombotic stroke, 277
Thrombotic thrombocytopenic purpura (TTP), 42, 353, See also Immune thrombocytopenic purpura (ITP)
Tiselius, Arne, 6
Tissue factor (TF), 81
Tissue factor pathway inhibitor (TFPI), 148
Tissue plasmin activator (tPA), 259, 260, 261, 265
Tissue-type plasminogen activator (tPA), 312
Titmuss, Richard, 12
Toll arrangement, 458
Toll fractionation, 17
Toll manufacturing, 458
Topical plasminogen drops, 317
Torcetrapib, 273
Total proteins, of IVIG preparations, 192
Toxicity
of cell-free hemoglobin, 325, 326
of early plasmin preparations, 260
of Factor X concentrate, 111
of haptoglobin, 331
Toxicological studies, plasmin-related, 266
Toxicology
nonclinical, 406
plasmin-related, 266, 267
Toxin neutralization, 208
Tranexamic acid, 142
Transferrin, 301–310
accompanying IVIG preparations, 197
binding capacity of, 303
biochemistry of, 302, 303
characterization of, 305, 306
clinical applications for, 306
clinical development of, 306, 307
future trends in, 306, 307
iron-binding capacity of, 301, 306
manufacture of, 303–305
mechanism of action of, 301, 302
physiology of, 301
as a targeting molecule, 307
Transferrin-dependent iron uptake, 302
Transferrin formulations, 304
Transferrin preparations, 304, 306
Transferrin purification, 304, 305
Transferrin-receptor complex, 302
Transferrin receptors, 302
Transferrin substitution therapy, 306
Transferrin synthesis, 301
Transfusion
early history of, 3–5
plasma collected for, 423–425
Transfusion complications, 353
Transfusion Medicine Epidemiological Review (TMER), 372, 373
Transfusion related acute lung injury (TRALI), 221, 351, 352
risk of, 352, 353
Transfusion Sanguine d’Urgence (TSU), 11
Transfusion substitutes, developing, 5–7
Transfusion-transmitted (TT) sCJD (TTS CJD) infections, 373
Transfusion-transmitted (TT) vCJD (TTvCJD) infections, 372, 373
Transgenic animals, recombinant FVIII production in, 38
Transgenic plants, 283
therapeutic proteins from, 295
Transgenic rhATIIIIs, 151
Transmembrane pressure (TMP), 442
Transmissible spongiform encephalitis/encephalopathies (TSEs), 35, See also TSE entries
albumin and, 177
future issues related to, 376, 377
histopathological changes of, 369, 370
new developments concerning, 376, 377
plasma products and, 369–380
Transplacental blood transfer, 218
Treatment-emergent adverse events (TEAEs), 268
Triacylglycerol (TAG), 284
Triglycerides, 284
Trinuclear cluster, of ceruloplasmin, 337
Trypsin-inhibitory activity, of alpha-1-PI, 232
Trypsone®, 233
TSE clearance studies, 375, 376. See also Transmissible spongiform encephalitis/encephalopathies (TSEs)
TSE diseases, classification of human, 370
TSE infections, transmissibility of, 369
TSE infectivity, in blood, 371–373
TSE infectivity reduction studies for blood components, 374
for plasma products, 374–376
TSE infectivity removal, 375
TSE removal methods, 36, 151
TSE screening tests, 376
Tubular-bowl centrifuge designs, 167
Tubular centrifuges, 440
Tumor necrosis factor (TNF), 321
Turbidity monitoring, in centrifuge design, 167
Turecek, Peter L., xii, 49
12–24 h plasma, 432
Type 1 diabetes, 238. See also Diabetes
Tzanck, Arnault, 11
Ultrafiltration, 234, 328
in albumin manufacture, 168
in plasma fractionation, 442
Ultrafiltration membranes, 442
Ultrasound, in HDFN treatment, 217, 218
Ultraviolet light inactivation, 36. See also UV-irradiation
UMAN Complex D.I., 71
Uniplas, 346
UniProt, 322
United States. See also American entries;
Code of Federal Regulations (CFR);
Food and Drug Administration (FDA); Government–company relationships; National entries; U.S. entries
AAT deficiency in, 228
fibrin glues in, 137
immune globulin product sales in, 185
legal plasma-regulatory documents in, 385
licensure requirements in, 405, 406
plasma collection/recovery in, 21, 423, 424
plasma manufacture in, 384
plasma standards in, 425
quality control systems in, 387
rare disorders in, 101
<table>
<thead>
<tr>
<th>Index Entry</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ward, Gordon R.</td>
<td>4</td>
</tr>
<tr>
<td>Warfarin reversal</td>
<td>68</td>
</tr>
<tr>
<td>Water albumin and</td>
<td>161</td>
</tr>
<tr>
<td>fibrinogen and</td>
<td>118</td>
</tr>
<tr>
<td>Watt, J. G.</td>
<td>11</td>
</tr>
<tr>
<td>Weibel–Palade bodies</td>
<td>42</td>
</tr>
<tr>
<td>Welfide Corporation</td>
<td>17, 18</td>
</tr>
<tr>
<td>West Nile virus (WNV)</td>
<td>363</td>
</tr>
<tr>
<td>White blood cells (WBC), depletion of</td>
<td>374</td>
</tr>
<tr>
<td>WHO guidance document</td>
<td>386. See also WHO guidance document World Health Organization (WHO)</td>
</tr>
<tr>
<td>Whole blood-derived plasma</td>
<td>423, 424</td>
</tr>
<tr>
<td>Whole-blood transfusion, risks associated with</td>
<td>4</td>
</tr>
<tr>
<td>Wilate</td>
<td>45</td>
</tr>
<tr>
<td>Wilfactia®</td>
<td>45</td>
</tr>
<tr>
<td>Willfact®</td>
<td>45</td>
</tr>
<tr>
<td>Wilson–Konovalov disease</td>
<td>337, 338</td>
</tr>
<tr>
<td>Winnipeg process</td>
<td>221</td>
</tr>
<tr>
<td>World Health Organization (WHO)</td>
<td>467. See also WHO guidance document Worldwide plasma market</td>
</tr>
<tr>
<td>Zentrallaboratorium, Blutspendedienst SRK (ZLB)</td>
<td>11, 12</td>
</tr>
<tr>
<td>Zymogen Factor X activation</td>
<td>107</td>
</tr>
<tr>
<td>Zymogens</td>
<td>51–53, 59</td>
</tr>
<tr>
<td>Zemaira®</td>
<td>227, 231, 234</td>
</tr>
<tr>
<td>Zemaira purification process</td>
<td>234, 236</td>
</tr>
<tr>
<td>Zwitter, Sacha</td>
<td>xii, 241</td>
</tr>
<tr>
<td>Zeerleder, Sacha</td>
<td>xii, 241</td>
</tr>
<tr>
<td>Wound healing, fibrinogen and</td>
<td>117</td>
</tr>
<tr>
<td>Wouters, Diana</td>
<td>xii, 241</td>
</tr>
<tr>
<td>Zentrrallaboratorium, Blutspendedienst SRK (ZLB)</td>
<td>11, 12</td>
</tr>
<tr>
<td>Zymogen Factor X activation</td>
<td>107</td>
</tr>
<tr>
<td>Zymogens</td>
<td>51–53, 59</td>
</tr>
</tbody>
</table>